Acumen Capital reaffirmed their buy rating on shares of Viemed Healthcare (NASDAQ:VMD) in a research report sent to investors on Wednesday, Stock Target Advisor reports. The firm currently has a $12.00 price objective on the stock.
Several other research firms have also issued reports on VMD. ValuEngine lowered Viemed Healthcare from a hold rating to a sell rating in a research note on Thursday, October 22nd. Bloom Burton restated an accumulate rating on shares of Viemed Healthcare in a research note on Monday, October 19th.
NASDAQ:VMD opened at $8.11 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.34 and a current ratio of 1.55. The company has a market capitalization of $316.98 million, a price-to-earnings ratio of 11.26 and a beta of 1.52. Viemed Healthcare has a 12-month low of $2.44 and a 12-month high of $11.98.
About Viemed Healthcare
Viemed Healthcare, Inc, through its subsidiaries, provides in-home durable medical equipment and health care solutions to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen units, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services.
Read More: What are no-load funds?
Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.